John J. Reddington
Direktor/Vorstandsmitglied bei 3Brain AG
Aktive Positionen von John J. Reddington
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
3Brain AG
3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | Direktor/Vorstandsmitglied | - | - |
Grid News Bureau LLC | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von John J. Reddington
Ehemalige bekannte Positionen von John J. Reddington
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Morris Animal Foundation
Morris Animal Foundation Miscellaneous Commercial ServicesCommercial Services Morris Animal Foundation operates as an animal health charity. It helps support the advancement of veterinary medicine and funds veterinary research for companion animals, horses, and wildlife. The company was founded by Mark Morris Sr. in 1948 and is headquartered in Denver, CO. | Vorstandsvorsitzender | 17.05.2016 | 01.02.2018 |
Präsident | 17.05.2016 | 01.02.2018 | |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Geschäftsführer | 01.05.2003 | 01.11.2006 |
Ausbildung von John J. Reddington
Washington State University | Doctorate Degree |
The University of Texas at Austin | Graduate Degree |
Rice University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Schweiz | 2 |
Operativ
Director/Board Member | 2 |
Chief Operating Officer | 1 |
Doctorate Degree | 1 |
Sektoral
Consumer Services | 4 |
Health Technology | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
Morris Animal Foundation
Morris Animal Foundation Miscellaneous Commercial ServicesCommercial Services Morris Animal Foundation operates as an animal health charity. It helps support the advancement of veterinary medicine and funds veterinary research for companion animals, horses, and wildlife. The company was founded by Mark Morris Sr. in 1948 and is headquartered in Denver, CO. | Commercial Services |
3Brain AG
3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | Technology Services |
Grid News Bureau LLC |
- Börse
- Insiders
- John J. Reddington
- Erfahrung